Dietary and pharmacological antioxidants in atherosclerosis
- 1 December 1999
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 10 (6) , 589-598
- https://doi.org/10.1097/00041433-199912000-00014
Abstract
Antioxidants that inhibit LDL oxidation are thought to be potential anti-atherogenic compounds. The results of major human randomized trials with antioxidants have, however, been disappointing, except for probucol, which consistently inhibits restenosis. Similarly, animal intervention studies show that antioxidants do not generally inhibit atherosclerosis, although some compounds provide protection. Direct evidence for the oxidation of LDL causing atherosclerosis is needed. This article summarizes results from antioxidant intervention studies, and highlights some of the key issues that need to be addressed to link biochemical changes in the arterial wall more directly to the oxidation theory of atherosclerosis.Keywords
This publication has 92 references indexed in Scilit:
- Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesisAtherosclerosis, 1998
- Antioxidants and Atherosclerotic Heart DiseaseNew England Journal of Medicine, 1997
- Antioxidants in cardiovascular disease: Randomized trialsNutrition, 1996
- The Yin and Yang of Oxidation in the Development of the Fatty StreakArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine.Journal of Clinical Investigation, 1992
- The antioxidant butylated hydroxytoluene protects against atherosclerosis.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
- Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiologyThe American Journal of Clinical Nutrition, 1991
- Book ReviewAmbulatory Pediatric CareNew England Journal of Medicine, 1989
- Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.Proceedings of the National Academy of Sciences, 1987
- Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.Proceedings of the National Academy of Sciences, 1987